bioAffinity Technologies announces $4 million direct financing

bioAffinity Technologies said it entered a definitive agreement for a registered direct offering priced at-the-market under Nasdaq rules, with concurrent private placement warrants. The company expects gross proceeds of about $4 million before fees and expenses.